Alignment Healthcare's Stock Plummets Amidst CMS Rating Downgrade Concerns

Alignment Healthcare Faces Stock Challenges Amid Downgrade Concerns



On October 9, 2026, Alignment Healthcare, Inc. (NASDAQ: ALHC) experienced a dramatic decrease in its stock price, plummeting 13% to a low of $7.55 per share. This decline is largely attributed to the Centers for Medicare and Medicaid Services (CMS) downgrading its 2027 Star Rating for the company's California HMO health plan contract, known as H3815, from 4.0 stars to 3.5 stars. This rating downgrade is particularly significant, as H3815 accounts for 75% of Alignment Healthcare's health plan membership.

The downgrade came just as the market was beginning to question the performance metrics used by CMS to evaluate H3815. Last July, during an investor conference, concerns were raised regarding the increasing difficulty of achieving high Star Ratings. Despite investors expressing doubt, CEO John Kao assured them of the company's strong standing. However, skepticism loomed over the stock, causing a 20% drop in share price on that day.

Further inquiries during a September healthcare conference resulted in a lack of transparency from Alignment's management regarding the company's performance metrics and the implications for future bonuses tied to Star Ratings. CEO Kao's refusal to discuss the ratings only fueled investor unease, leading to another 20% drop in stock prices following those exchanges.

The fallout continued when, on October 8, 2026, the company revealed through a current report filed with the SEC that CMS had indeed downgraded H3815 to a 3.5-star rating. The announcement confirmed that this downgrade would directly impact the company's quality bonus payments for fiscal 2028, resulting in H3815 being ineligible for these critical CMS funds. Investors reacted swiftly, causing an additional 13% drop in share prices the following day.

From the reassurance shared by Kao on July 30 to the realization of the lowered Star Ratings by October 9, Alignment’s shares saw a staggering decline of almost 59%, translating to a market capitalization loss exceeding $2.2 billion over this brief period.

The ongoing investigation, led by Hagens Berman, a national shareholder rights firm, is probing into Alignment's management and their understanding of the implications of H3815's Star Rating cut. They aim to determine whether the company's leadership was aware of the precarious position regarding the cut points and their eligibility for bonus payments from CMS. Moreover, the investigation is appealing to potential whistleblowers with insider knowledge about Alignment's operations and ratings, offering rewards for valuable information.

Hagens Berman specializes in pursuing corporate accountability, representing a wide array of clients impacted by corporate misconduct. They have secured over $2.9 billion in various litigations on behalf of investors, whistleblowers, and consumers.

As the investigation unfolds, the future of Alignment Healthcare’s stock and its business model remains uncertain. The financial community will be watching closely how the company navigates these challenges and whether it can restore investor confidence amidst its current turmoil. Stakeholders, including investors and members of its health plans, will undoubtedly feel the repercussions of this situation in the months to come.

Topics Financial Services & Investing)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.